European Archives - Page 855 of 983 - European Medical Journal

Continue
EMJ
14 Jun 2016

Next-generation sequencing to guide treatment decision-making

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Matthias Löhr, MD, PhD, from Karolinska Institutet, Stockholm…
EMJ
14 Jun 2016

Introducing next-generation sequencing into the clinical care of cancer

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Matthias Löhr, MD, PhD, from Karolinska Institutet, Stockholm…
EMJ
14 Jun 2016

Early versus delayed use of tyrosine kinase inhibitors for thyroid cancer

Recent advances in the biological understanding of thyroid cancer have led to the development of targeted therapies, such as the tyrosine kinase…
EMJ
14 Jun 2016

Updating the treatment algorithm for metastatic melanoma

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Axel Hauschild, MD, from University of Kiel, Kiel, Germany…
EMJ
14 Jun 2016

Changing the treatment landscape of metastatic melanoma

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Axel Hauschild, MD, from University of Kiel, Kiel, Germany…
EMJ
14 Jun 2016

Clinical decision-making for pancreatic cancer

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Thomas Seufferlein, MD, from University of Ulm, Ulm, Germany…
EMJ
14 Jun 2016

The significance of BRCA mutations in pancreatic cancer

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Thomas Seufferlein, MD, from University of Ulm, Ulm, Germany…
EMJ
14 Jun 2016

Treatment of pancreatic cancer: Overview of the continued progress

Pancreatic cancer is a leading cause of cancer-related deaths in developed countries. At the German Cancer Congress 2016, held in Berlin, Germany, from…
13 Jun 2016

Daratumumab (DARZALEX®) Combination Therapy Significantly Extended Progression-Free Survival in Previously Treated Patients with Multiple Myeloma

Beerse, Belgium, 5 June 2016 – Data from the Phase 3 MMY3004 (CASTOR) clinical trial show the immunotherapy daratumumab (DARZALEX®) in combination with a…
13 Jun 2016

Helsinn Group Hosts a Satellite Symposium on Shared Decision Making in Supportive Care, at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) Annual Meeting 2016 on June 24th

Lugano, Switzerland, June 13, 2016 – Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announces that it is…